FDA lorvotuzumab mertansine coverage for business development, investment, and market access teams
The FDA has granted approval for IMGN-901, marking a significant advancement in treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
